Myriad Genetics (MYGN) closed at $5.67 on November 10, 2026, down 1.2% from the previous close, on volume of 1,056,433 shares (30-day average 2,711,129).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
AVAX One brings total convertible debt balance to zero
Seeking Alpha News (Tue, 10-Nov 4:45 PM ET)
TipRanks (Tue, 10-Nov 6:50 AM ET)
Myriad Genetics Grants Retention Stock Options to Executives
TipRanks (Mon, 9-Nov 5:28 PM ET)
Regulatory Hurdles Put Myriad Genetics’ $210 Million Prenatal Health Sale to LabCorp at Risk
TipRanks (Sun, 8-Nov 1:00 AM ET)
Globe Newswire (Wed, 4-Nov 4:05 PM ET)
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Globe Newswire (Thu, 22-Oct 9:05 AM ET)
Market Chameleon (Tue, 20-Oct 5:52 AM ET)
Globe Newswire (Tue, 20-Oct 8:30 AM ET)
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026
Globe Newswire (Thu, 15-Oct 4:05 PM ET)
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
Myriad Genetics trades on the NASDAQ stock market under the symbol MYGN.
As of November 10, 2026, MYGN stock price declined to $5.67 with 1,056,433 million shares trading.
MYGN has a beta of -0.11, meaning it tends to be less sensitive to market movements. MYGN has a correlation of 0.00 to the broad based SPY ETF.
MYGN has a market cap of $535.49 million. This is considered a Small Cap stock.
Last quarter Myriad Genetics reported $203 million in Revenue and -$.11 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.10.
In the last 3 years, MYGN traded as high as $29.30 and as low as $2.74.
The top ETF exchange traded funds that MYGN belongs to (by Net Assets): XBI, IWM, VTI, IWN, VXF.
MYGN has underperformed the market in the last year with a price return of -10.0% while the SPY ETF gained +12.9%. However, in the short term, MYGN had mixed performance relative to the market. It has outperformed in the last 3 months, returning +73.9% vs -2.8% return in SPY. But in the last 2 weeks, MYGN shares have been beat by the market, returning -5.8% compared to an SPY return of -2.0%.
MYGN support price is $5.46 and resistance is $6.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MYGN shares will trade within this expected range on the day.
